165 related articles for article (PubMed ID: 20627557)
21. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
[TBL] [Abstract][Full Text] [Related]
22. A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1.
Rettenmaier TJ; Sadowsky JD; Thomsen ND; Chen SC; Doak AK; Arkin MR; Wells JA
Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18590-5. PubMed ID: 25518860
[TBL] [Abstract][Full Text] [Related]
23. Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
Kim KH; Wissner A; Floyd MB; Fraser HL; Wang YD; Dushin RG; Hu Y; Olland A; Guo B; Arndt K
Bioorg Med Chem Lett; 2009 Sep; 19(17):5225-8. PubMed ID: 19628388
[TBL] [Abstract][Full Text] [Related]
24. N-(4-(6,7-Disubstituted-quinolin-4-yloxy)-3-fluorophenyl)-2-oxo-3-phenylimidazolidine-1-carboxamides: a novel series of dual c-Met/VEGFR2 receptor tyrosine kinase inhibitors.
Mannion M; Raeppel S; Claridge S; Zhou N; Saavedra O; Isakovic L; Zhan L; Gaudette F; Raeppel F; Déziel R; Beaulieu N; Nguyen H; Chute I; Beaulieu C; Dupont I; Robert MF; Lefebvre S; Dubay M; Rahil J; Wang J; Ste-Croix H; Robert Macleod A; Besterman JM; Vaisburg A
Bioorg Med Chem Lett; 2009 Dec; 19(23):6552-6. PubMed ID: 19854051
[TBL] [Abstract][Full Text] [Related]
25. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
26. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
27. Structure-based optimization of potent PDK1 inhibitors.
Angiolini M; Banfi P; Casale E; Casuscelli F; Fiorelli C; Saccardo MB; Silvagni M; Zuccotto F
Bioorg Med Chem Lett; 2010 Jul; 20(14):4095-9. PubMed ID: 20621725
[TBL] [Abstract][Full Text] [Related]
28. Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Chai L; Chaffee SC; Deak HL; Epstein LF; Faust T; Gallant P; Gore A; Gu Y; Henkle B; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; Zhao H; Zhu L; Zhu X
J Med Chem; 2008 Mar; 51(6):1681-94. PubMed ID: 18321037
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and evaluation of debromohymenialdisine-derived Chk2 inhibitors.
Saleem RS; Lansdell TA; Tepe JJ
Bioorg Med Chem; 2012 Feb; 20(4):1475-81. PubMed ID: 22285028
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of substituted 3-anilino-quinolin-2(1H)-ones as PDK1 inhibitors.
O'Brien NJ; Brzozowski M; Wilson DJ; Deady LW; Abbott BM
Bioorg Med Chem; 2014 Jul; 22(14):3781-90. PubMed ID: 24856302
[TBL] [Abstract][Full Text] [Related]
31. AGC kinases, mechanisms of regulation and innovative drug development.
Leroux AE; Schulze JO; Biondi RM
Semin Cancer Biol; 2018 Feb; 48():1-17. PubMed ID: 28591657
[TBL] [Abstract][Full Text] [Related]
32. Combined 3D-QSAR modeling and molecular docking study on indolinone derivatives as inhibitors of 3-phosphoinositide-dependent protein kinase-1.
AbdulHameed MD; Hamza A; Liu J; Zhan CG
J Chem Inf Model; 2008 Sep; 48(9):1760-72. PubMed ID: 18717540
[TBL] [Abstract][Full Text] [Related]
33. Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
Abraham S; Hadd MJ; Tran L; Vickers T; Sindac J; Milanov ZV; Holladay MW; Bhagwat SS; Hua H; Ford Pulido JM; Cramer MD; Gitnick D; James J; Dao A; Belli B; Armstrong RC; Treiber DK; Liu G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5296-300. PubMed ID: 21802948
[TBL] [Abstract][Full Text] [Related]
34. Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C-terminal residues of PKA.
Biondi RM; Cheung PC; Casamayor A; Deak M; Currie RA; Alessi DR
EMBO J; 2000 Mar; 19(5):979-88. PubMed ID: 10698939
[TBL] [Abstract][Full Text] [Related]
35. Structure-based lead identification of ATP-competitive MK2 inhibitors.
Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
[TBL] [Abstract][Full Text] [Related]
36. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2.
Hilton S; Naud S; Caldwell JJ; Boxall K; Burns S; Anderson VE; Antoni L; Allen CE; Pearl LH; Oliver AW; Wynne Aherne G; Garrett MD; Collins I
Bioorg Med Chem; 2010 Jan; 18(2):707-18. PubMed ID: 20022510
[TBL] [Abstract][Full Text] [Related]
37. Identification of Ustilago maydis Aurora kinase as a novel antifungal target.
Tückmantel S; Greul JN; Janning P; Brockmeyer A; Grütter C; Simard JR; Gutbrod O; Beck ME; Tietjen K; Rauh D; Schreier PH
ACS Chem Biol; 2011 Sep; 6(9):926-33. PubMed ID: 21671622
[TBL] [Abstract][Full Text] [Related]
38. Molecular mechanism of regulation of the atypical protein kinase C by N-terminal domains and an allosteric small compound.
Zhang H; Neimanis S; Lopez-Garcia LA; Arencibia JM; Amon S; Stroba A; Zeuzem S; Proschak E; Stark H; Bauer AF; Busschots K; Jørgensen TJ; Engel M; Schulze JO; Biondi RM
Chem Biol; 2014 Jun; 21(6):754-65. PubMed ID: 24836908
[TBL] [Abstract][Full Text] [Related]
39. Selective 3-phosphoinositide-dependent kinase 1 (PDK1) inhibitors: dissecting the function and pharmacology of PDK1.
Medina JR
J Med Chem; 2013 Apr; 56(7):2726-37. PubMed ID: 23448267
[TBL] [Abstract][Full Text] [Related]
40. Aza-stilbenes as potent and selective c-RAF inhibitors.
McDonald O; Lackey K; Davis-Ward R; Wood E; Samano V; Maloney P; Deanda F; Hunter R
Bioorg Med Chem Lett; 2006 Oct; 16(20):5378-83. PubMed ID: 16890436
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
